Orthobiologics for Osteoarthritis

NewsBot · May 18, 2022

Members do not see these Ads. Sign Up.
Orthobiologics for the Management of Early Arthritis in the Middle-Aged Athlete
Rauck, Ryan C. MD et al
Sports Medicine and Arthroscopy Review: June 2022 - Volume 30 - Issue 2 - p e9-e16

This article is dedicated to the use of orthobiologic therapies in the management of early osteoarthritis in middle-aged athletes. Understanding a patient’s presenting symptoms, physical examination, imaging results, and goals is of critical importance in applying orthobiologic therapies. The field of orthobiologics is expanding at a rapid pace, and the clinical studies examining the utility of each treatment lag behind the direct-to-consumer marketing that leads to these products being used. Here we provide a review of the available treatments, emerging treatments, and the current literature supporting or refuting their use. Currently studied orthobiologics include autologous and allogenic cell therapies, autologous blood products, hyaluronic acid, gene therapies, Wnt inhibitors, and a variety of systemic treatments.
Click to expand...

NewsBot · May 18, 2022

Related Thread:
Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis

NewsBot · Dec 24, 2023

Reprogramming Macrophage Polarization, Depleting ROS by Astaxanthin and Thioketal-Containing Polymers Delivering Rapamycin for Osteoarthritis Treatment
Huiyun Li et al
Adv Sci (Weinh). 2023 Dec 14

Osteoarthritis (OA) is a chronic joint disease characterized by synovitis and joint cartilage destruction. The severity of OA is highly associated with the imbalance between M1 and M2 synovial macrophages. In this study, a novel strategy is designed to modulate macrophage polarization by reducing intracellular reactive oxygen species (ROS) levels and regulating mitochondrial function. A ROS-responsive polymer is synthesized to self-assemble with astaxanthin and autophagy activator rapamycin to form nanoparticles (NP@PolyRHAPM ). In vitro experiments show that NP@PolyRHAPM significantly reduced intracellular ROS levels. Furthermore, NP@PolyRHAPM restored mitochondrial membrane potential, increased glutathione (GSH) levels, and promoted intracellular autophagy, hence successfully repolarizing M1 macrophages into the M2 phenotype. This repolarization enhanced chondrocyte proliferation and vitality while inhibiting apoptosis. In vivo experiments utilizing an anterior cruciate ligament transection (ACLT)-induced OA mouse model revealed the anti-inflammatory and cartilage-protective effects of NP@PolyRHAPM , effectively mitigating OA progression. Consequently, the findings suggest that intra-articular delivery of ROS-responsive nanocarrier systems holds significant promise as a potential and effective therapeutic strategy for OA treatment.
Click to expand...

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Is there an association between plantar fasciitis and knee osteoarthritis?

Neuropathic pain associated with first metatarsophalangeal joint osteoarthritis

Plantar fasciitis in patients with knee osteoarthritis

Age and onset of osteoarthritis

Foot orthoses for first metatarsophalangeal joint osteoarthritis

International Foot and Ankle Osteoarthritis Consortium review and research agenda

Hallux valgus associated osteoarthritis

Share This Page